Exploring Ginkgo Bioworks Holdings, Inc. (DNA) Investor Profile: Who’s Buying and Why?

Have you been keeping an eye on Ginkgo Bioworks Holdings, Inc. (DNA) and wondering who's investing and why? As of April 2025, institutional investors hold significant positions in Ginkgo Bioworks, with 78.63% of the stock owned by these entities. But with the stock price down by 81% in 2024, and a -9.71% decrease in revenue, what's driving investor sentiment? Is it the company's potential for highly automated biopharma manufacturing, or the cost reduction strategies aimed at achieving positive adjusted EBITDA by the end of 2026? Let's dive into the details of Ginkgo Bioworks' investor profile to uncover the motivations behind the buys and sells.

Ginkgo Bioworks Holdings, Inc. (DNA) Who Invests in [Company Name] and Why?

Understanding the investor profile of Ginkgo Bioworks Holdings, Inc. (DNA) involves examining the diverse range of entities and individuals that hold its stock, as well as their motivations for investing. This encompasses a variety of investor types, each with their own strategies and expectations.

Key investor types in Ginkgo Bioworks Holdings, Inc. (DNA) typically include:

• Retail Investors: Individual investors who buy and sell shares for their own accounts. Their investment decisions are often based on personal research, recommendations, and understanding of the company's potential.
• Institutional Investors: These are organizations that invest on behalf of others. They include:
  • Mutual Funds: These funds pool money from many investors to purchase a diversified portfolio of stocks.
  • Pension Funds: They invest to fund retirement benefits for their members.
  • Hedge Funds: These are investment partnerships that use more aggressive strategies to maximize returns.
  • Insurance Companies: They invest to cover future claims.
  • Endowments: These are funds donated to non-profit organizations like universities and hospitals.

The motivations behind investing in Ginkgo Bioworks Holdings, Inc. (DNA) can be varied and are often linked to the company's unique position in the biotechnology industry. Some common reasons include:

• Growth Prospects: Ginkgo Bioworks operates in the rapidly expanding field of synthetic biology. Investors may be attracted by the potential for high growth as the company scales its platform and expands its partnerships.
• Market Position: As a prominent player in synthetic biology, Ginkgo's established platform and partnerships provide a competitive advantage. This market position can be appealing to investors looking for companies with a strong foothold in emerging industries.

Investment strategies among Ginkgo Bioworks Holdings, Inc. (DNA) investors can differ significantly based on their investment goals and risk tolerance:

• Long-Term Holding: Some investors may adopt a long-term holding strategy, focusing on the company's potential for sustained growth over several years. This approach is common among institutional investors and those who believe in the long-term prospects of synthetic biology.
• Short-Term Trading: Other investors may engage in short-term trading, seeking to profit from fluctuations in the stock price. This strategy is more common among hedge funds and individual traders.
• Value Investing: Value investors look for companies that they believe are undervalued by the market. They may see Ginkgo Bioworks as a company with intrinsic value that is not fully reflected in its current stock price.

For those interested in learning more about Ginkgo Bioworks' core values and strategic vision, you can explore: Mission Statement, Vision, & Core Values of Ginkgo Bioworks Holdings, Inc. (DNA).

Below is a hypothetical overview of key investor types and their approaches to Ginkgo Bioworks Holdings, Inc. (DNA), presented in table form for clarity.

Understanding the composition and motivations of Ginkgo Bioworks Holdings, Inc. (DNA)'s investor base provides valuable insights into market sentiment and potential future stock performance. This information is crucial for both current and prospective investors.

Ginkgo Bioworks Holdings, Inc. (DNA) Institutional Ownership and Major Shareholders

Institutional ownership in Ginkgo Bioworks Holdings, Inc. (DNA) indicates the extent to which large organizations like hedge funds, mutual funds, and insurance companies own the company's shares. It's a key factor for investors to consider, as it can influence a stock's price and stability. Here's a detailed look at the institutional ownership of Ginkgo Bioworks Holdings, Inc. (DNA).

As of April 2025, 228 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 33,384,875 shares. Institutional ownership accounts for 78.63% of Ginkgo Bioworks stock.

Here is a list of the top institutional investors in Ginkgo Bioworks Holdings, Inc. (DNA) based on recent filings:

• Bank of America Corp /de/
• Viking Global Investors Lp
• Baillie Gifford & Co
• Vanguard Group Inc
• Anchorage Capital Group, L.L.C.
• EcoR1 Capital, LLC
• BlackRock, Inc.
• Opaleye Management Inc.
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• Legal & General Group Plc

Major shareholders include individual investors, mutual funds, hedge funds, or institutions. A Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. A Schedule 13G indicates a passive investment of over 5%.

Changes in institutional ownership can provide insights into the sentiment of major investors. Recent data shows the following activities:

• Total institutional holdings decreased by 3.2% in the last quarter.
• Of the 161 institutional investors that purchased Ginkgo Bioworks stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares:
  • ARK Investment Management LLC ($33.85M)
  • Sumitomo Mitsui Trust Holdings Inc. ($21.23M)
  • Norges Bank ($14.77M)
  • AQR Capital Management LLC ($10.36M)
  • Monaco Asset Management SAM ($9.81M)
  • Lingotto Investment Management LLP ($8.51M)
  • Welch & Forbes LLC ($7M)
• Institutional investors have bought a total of 165,119,329 shares in the last 24 months.

The level of institutional ownership can significantly impact a company's stock price. Institutional investors often have substantial resources and can influence stock prices through large volume trading. Moreover, changes in their positions can signal confidence or concern about a company's prospects.

For instance, a Zacks Rank #1 (Strong Buy) upgrade for Ginkgo Bioworks reflects an upward trend in earnings estimates. Institutional investors often rely on these earnings estimates to determine a fair value for a company's shares, which can drive buying pressure and increase the stock price.

However, it's important to note that substantial institutional holdings can also lead to increased volatility. If institutions decide to sell their shares, it can create a downward spiral in the stock price, particularly if the company is at risk of being delisted from major exchanges like the NYSE.

Here is some additional data regarding institutional ownership:

As of April 17, 2025, the share price of Ginkgo Bioworks Holdings, Inc. was $7.85 per share, with a market cap of $345.42 million.

For more insights into Ginkgo Bioworks Holdings, Inc. (DNA), explore: Ginkgo Bioworks Holdings, Inc. (DNA): History, Ownership, Mission, How It Works & Makes Money

Ginkgo Bioworks Holdings, Inc. (DNA) Key Investors and Their Impact on Ginkgo Bioworks Holdings, Inc. (DNA)

Understanding the investor profile of Ginkgo Bioworks Holdings, Inc. (DNA) provides valuable insights into the company's stability, growth potential, and strategic direction. Examining who is investing in Ginkgo and their recent activities can reveal a lot about market sentiment and future expectations.

While specific real-time data on all investors and their direct impact can fluctuate, here's a general overview based on available information and typical investor influence scenarios:

Notable Investors:

Institutional investors, venture capital firms specializing in biotechnology, and strategic partners often constitute a significant portion of Ginkgo Bioworks' investor base. These entities typically hold large stakes and can exert considerable influence. Some examples of the types of investors who may be significant include:

• Vanguard Group: Known for its passive investment strategies and substantial holdings across various sectors.
• BlackRock Fund Advisors: Another major institutional investor with a diverse portfolio.
• ARK Investment Management: Known for its focus on disruptive innovation, particularly in genomics and biotechnology.

Investor Influence:

The influence of these investors can manifest in several ways:

• Strategic Direction: Major investors can influence company strategy through board representation or by engaging with management on key decisions.
• Stock Performance: Large institutional holdings can impact stock price stability and trading volume. Significant buying or selling activity can lead to price fluctuations.
• Corporate Governance: Investors can push for changes in corporate governance practices, such as executive compensation or board composition.
• Access to Capital: Strong investor backing can facilitate access to additional capital through secondary offerings or debt financing.

Recent Moves:

Keeping track of recent moves by major investors is crucial. Here's what to look for:

• Increased or Decreased Stakes: SEC filings (e.g., 13F filings) reveal changes in institutional ownership. Significant increases or decreases in holdings can signal confidence or concern about the company's prospects.
• Activist Campaigns: Although not always the case, activist investors may emerge, advocating for specific changes in company strategy or operations.
• Public Statements: Monitoring public statements or interviews by key investors can provide insights into their views on the company's performance and future direction.

To illustrate potential investor activity, consider the following hypothetical example presented in a table format:

It is important to note that this is a hypothetical example for illustrative purposes only.

Analyzing investor profiles and their recent activities requires continuous monitoring of financial news, SEC filings, and investor relations updates. This information helps stakeholders understand the dynamics influencing Ginkgo Bioworks Holdings, Inc. (DNA) and make informed decisions.

For more information on Ginkgo Bioworks' mission, vision, and core values, you can visit: Mission Statement, Vision, & Core Values of Ginkgo Bioworks Holdings, Inc. (DNA).

Ginkgo Bioworks Holdings, Inc. (DNA) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Ginkgo Bioworks Holdings, Inc. (DNA). This section examines the current sentiment of major shareholders, recent market reactions to ownership changes, and insights from analysts on the impact of key investors on the company's future.

As of April 2025, 228 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 33,384,875 shares. Major shareholders include Bank of America Corp /de/, Viking Global Investors Lp, Baillie Gifford & Co, Vanguard Group Inc, Anchorage Capital Group, L.L.C., EcoR1 Capital, LLC, BlackRock, Inc., Opaleye Management Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Legal & General Group Plc.

To further explore the financial health of Ginkgo Bioworks Holdings, Inc. (DNA), consider reading: Breaking Down Ginkgo Bioworks Holdings, Inc. (DNA) Financial Health: Key Insights for Investors.

The share price of Ginkgo Bioworks Holdings, Inc. as of April 17, 2025, was $7.85 per share, a 7.53% increase from the prior week. However, on April 21, 2025, the share price was $7.34. Previously, on April 22, 2024, the share price was $33.71, representing a 78.24% decline over that period.

Recent data shows that 30.83% of Ginkgo Bioworks' floating shares are sold short, reflecting negative sentiment among investors. Ginkgo Bioworks shares have also experienced high volatility, with a 10.91% swing in a recent trading session and a three-day losing streak.

Here is a summary of analyst ratings for Ginkgo Bioworks:

• 7% Buy
• 42% Hold
• 50% Sell

The consensus price target has decreased, with analysts concerned about the company's weaker revenue and earnings outlook. The consensus of six analysts covering Ginkgo Bioworks Holdings provided estimates of US$182 million revenue in 2025, a 20% decline from the past 12 months. The loss per share is expected to reduce by 37% to US$6.32. Before this update, analysts had forecast revenues of US$204 million and losses of US$5.81 per share in 2025. The consensus price target fell 8.5% to US$8.60.

However, other analysts think Ginkgo Bioworks (DNA) could surge 41.59%, with a mean price target of $9.60. This comprises five short-term price targets ranging from $6 to $12.

Key points from analyst perspectives include:

• Analysts have cut revenue estimates, signaling a weaker outlook.
• Sales are expected to reverse, with a forecast 20% annualized revenue decline to the end of 2025, contrasting with a historical growth of 10% over the last five years.
• The consensus increased its forecast losses, with downgraded revenue estimates.

Despite some positive moving average signals, technical analysis suggests caution, as the stock faces resistance and is considered high risk for short-term traders.

Here is a table of major shareholders of Ginkgo Bioworks Holdings, Inc. (DNA):

Overall, approximately 61% of Ginkgo Bioworks' investor base is looking to short the stock, indicating that many traders are alarmed. However, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.